FDA

#Arvinas #Breast cancer #FDA #Oncology #Pfizer #PROTAC #Protein degradation

PROTAC degrader for ER+/HER2- breast cancer gets fast-tracked

Arvinas and Pfizer’s vepdegestrant (ARV-471) has received Fast Track Designation from the US Food and Drug Administration (FDA) for the treatment of patients with ER+/HER2- metastatic breast cancer. Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC) protein degrader designed to target and degrade the estrogen receptor (ER) protein. Fast Track… Read More

#Cancer Research #News #Regulatory

FDA headquarters
#Acute inflammatory conditions #FDA #Orphan drugs #Phase II trial #Revolo Biotherapeutics

Immune-resetting peptide gets orphan drug status

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revolo Biotherapeutics’ ‘1104 to treat eosinophilic esophagitis (EoE). EoE is a chronic, allergic inflammatory disease that is characterised by the accumulation of eosinophils in the lining of the esophagus. Inflammation caused by immune cells such as T… Read More

#News #Regulatory

RNA
#Business #FDA #mRNA #Oncology #Strand Therapeutics

Strand Therapeutics cuts workforce by 18%

Strand Therapeutics has announced an 18% cut to its workforce, just days after the US Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application to initiate a first-in-human trial of STX-001 for solid tumours. On LinkedIn the company said: “This week, Strand has made the difficult strategic… Read More

#Business & Investment #News #Trending News

Blood cancer
#Acute Myeloid Leukaemia #FDA #Oncology #Orphan drugs #Pleco Therapeutics #Rare disease

Novel leukaemia drug receives FDA Orphan Drug Designation

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics’s lead compound PTX-252 for the treatment of acute myeloid leukaemia (AML). PTX-252 is a novel molecular entity developed to increase the sensitivity of cancer cells to chemotherapy. The FDA’s designation acknowledges the potential of PTX-252… Read More

#Cancer Research #News #Regulatory

Pancreatic cancer
#AI #ASCO #Cancer research #Clinical trials #FDA #Neurology #Oncology #Orphan drugs #Pancreatic cancer #Rare disease

Phase IIa results for combination pancreatic cancer therapy  

BPGbio, an AI-powered biopharma that focuses on oncology, neurology, and rare diseases, has announced new data from a Phase IIa clinical trial of its lead candidate, BPM31510, in patients with advanced pancreatic cancers at the annual ASCO Gastrointestinal Cancers Symposium, being held 18-20 January 2024, in San Francisco. Read More

#Cancer Research #News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

New DDW Highlights podcast: 15 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week has seen a number of significant discoveries by researchers in academic institutions,… Read More

#News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

This week in drug discovery (8-12 January) 

News round-up for 8-12 January by DDW Digital Content Editor Diana Spencer. This week has seen a number of significant discoveries by researchers in academic institutions, in some cases in partnership with industry, emphasising the important role universities play in early-stage drug discovery. Perhaps most importantly,… Read More

#News

Cell and gene therapy
#Adverse event #Blood cancer #CAR-T #Cell and gene therapy #Cell therapy #FDA #Immunotherapy #ISCT #Oncology

Experts comment on FDA report on risk of T-cell malignancy  

The International Society for Cell & Gene Therapy (ISCT) has announced the publication in Nature Medicine of an expert consortium commentary addressing a recent statement from the US Food & Drug Administration (FDA) that it is investigating serious risk of T-cell malignancy in patients who received treatment with BCMA- or… Read More

#News #Regulatory

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

New DDW Highlights podcast for 8 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The start of 2024 has seen quite a bit of regulatory activity, with the… Read More

#News

#CAR-T #FDA #MHRA #Monoclonal antibodies #NMPA #Oncology #Regulatory

This week in drug discovery (1-5 January) 

News round-up for 1-5 January by DDW Digital Content Editor Diana Spencer. The start of 2024 has seen quite a bit of regulatory activity, with the UK MHRA’s launch of a new procedure for assessing drugs, along with significant regulatory approvals for therapeutics for cytomegalovirus, melanoma,… Read More

#News

FDA approval
#AstraZeneca #FDA #hATTR amyloidosis #Ionis #Phase III trial

Wainua approval marks important milestone in amyloidosis treatment

AstraZeneca and Ionis’ Wainua (eplontersen) has been approved in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults (hATTR-PN or ATTRv-PN). The approval by the US Food and Drug Administration (FDA) was based on the positive 35-week interim analysis from the NEURO-TTRansform Phase III trial. Read More

#News #Regulatory

Bladder cancer
#Antibody drug conjugate (ADC) #Astellas Pharma #Bladder cancer #FDA #Oncology #Pfizer #Phase III trial

Bladder cancer therapy reduces risk of death by 50%

The US Food and Drug Administration (FDA) has approved antibody-drug conjugate (ADC) enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial cancer (la/mUC). The approval is based on clinical data which found that Padcev plus pembrolizumab nearly doubled median overall survival compared to… Read More

#Editor's Choice #News #Regulatory

FDA
#Bluebird Bio #Cell and gene therapy #CRISPR #CRISPR Therapeutics #FDA #Sickle cell disorder (SCD) #Vertex

FDA approves gene therapies for sickle cell disease (with a warning)

The US Food and Drug Administration (FDA) has approved the first cell-based gene therapies for the treatment of sickle cell disease (SCD), Casgevy and Lyfgenia. Casgevy, from Vertex Pharmaceuticals and CRISPR Therapeutics, is also the first FDA-approved treatment to use CRISPR gene editing technology. However, the FDA added a black… Read More

#News #Regulatory #Trending News

Acute lymphoblastic leukemia
#Blood cancer #Eli Lilly #FDA #Leukaemia #Oncology

FDA approves second indication for Lilly’s BTK inhibitor Jaypirca

Eli Lilly’s Jaypirca (pirtobrutinib) has been approved in the US for lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL). It has been granted approval by the Food and Drug Administration (FDA) to treat patients who have received at least two lines of therapy, including a Bruton's tyrosine kinase (BTK) inhibitor and… Read More

#News #Regulatory

FDA approval
#FDA #Oncology #Regulatory #SpringWorks Therapeutics #Tumours

FDA approves first therapy for rare non-cancerous tumours

SpringWorks Therapeutics’ Ogsiveo (nirogacestat) has become the first drug to be approved for desmoid tumours in the US, following the go-ahead from the US Food and Drug Administration (FDA). Desmoid tumours are non-cancerous but can be locally aggressive. Although surgical removal has historically been the treatment of choice, there is… Read More

#News #Regulatory

FDA headquarters
#Adverse event #Blood cancer #CAR-T #Cell therapy #FDA #Immunotherapy #Oncology

FDA investigates safety of CAR-T cell immunotherapies

The Food and Drug Administration (FDA) said it will investigate the safety of BCMA- or CD19-directed autologous CAR-T cell immunotherapies, following reports of T cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in these patients. The reports were received from clinical trials and postmarketing adverse event (AE) data sources. Despite… Read More

#News #Regulatory #Trending News